Ken Griffin Alx Oncology Holdings Inc Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $164,688 - $495,191	28,200 Added 335.71%	36,600 $220,000
Q1 2024 May 15, 2024	SELL	$10.95 - $16.79 $20,805 - $31,901	-1,900 Reduced 18.45%	8,400 $93,000
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $47,137 - $150,724	9,800 Added 1960.0%	10,300 $153,000
Q3 2023 Nov 14, 2023	SELL	$4.19 - $7.35 $3,352 - $5,880	-800 Reduced 61.54%	500 $2,000
Q2 2023 Aug 14, 2023	BUY	$4.37 - $9.56 $4,807 - $10,516	1,100 Added 550.0%	1,300 $9,000
Q1 2023 May 15, 2023	SELL	$4.52 - $11.71 $5,423 - $14,052	-1,200 Reduced 85.71%	200 $0
Q4 2022 Feb 14, 2023	BUY	$9.51 - $12.95 $13,314 - $18,130	1,400 New	1,400 $15,000

116

41M

518K

142K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $62.3M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.